What is Safeplus International's stock symbol?
How much money does Safeplus International make?
Safeplus International trades on the OTCMKTS under the ticker symbol "ACAI."
Where are Safeplus International's headquarters?
Safeplus International has a market capitalization of $808.14 thousand.
Who is Safeplus International?
Safeplus International is headquartered at 15 SCHOEN PLACE, PITTSFORD NY, 14534.
Does Safeplus pay dividends?
Safeplus International Holdings Ltd. engages in the development of medical equipment, inventions, and technologies. It offers magnetic resonance imaging compatibility, MRI safety testing, and patents. The company was founded by Wilson Greatbatch and Michael L. Weiner on August 11, 1968 and is headquartered in Pittsford, NY.
What is Atai Life Sciences?
Safeplus International does not currently pay a dividend.
When does the lock up period end for Atai Life Sciences?
Atai Life Sciences N.V. focuses on operating as a holding company for ATAI Life Sciences AG that operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that are focused on multiple mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a GABA/nicotinic modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01 is a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
Is Atai Life Sciences a buy?
Atai Life Sciences' lock-up period expires on Wednesday, December 15th. Atai Life Sciences had issued 15,000,000 shares in its IPO on June 18th. The total size of the offering was $225,000,000 based on an initial share price of $15.00. After the end of the company's lock-up period, major shareholders and company insiders will be able to sell their shares of the company.
Does Atai Life Sciences pay dividends?
Atai Life Sciences has received a consensus rating of Buy. The company's average rating score is 2.92, and is based on 12 buy ratings, 1 hold rating, and no sell ratings.
